Omeros (NASDAQ:OMER) Director Arnold Hanish Sells 5,000 Shares of Stock

Omeros Corporation (NASDAQ:OMER) Director Arnold Hanish sold 5,000 shares of Omeros stock in a transaction on Wednesday, August 26th. The stock was sold at an average price of $18.53, for a total value of $92,650.00. Following the transaction, the director directly owned 5,000 shares of the company’s stock, valued at $92,650. This trade represents a 50.00% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink.

Omeros Trading Down 3.3%

Shares of NASDAQ OMER opened at $18.61 on Friday. The company’s 50-day moving average price is $12.64 and its 200 day moving average price is $12.03. Omeros Corporation has a 52 week low of $3.94 and a 52 week high of $19.65. The stock has a market cap of $1.35 billion, a price-to-earnings ratio of 14.54 and a beta of 2.54.

Omeros (NASDAQ:OMER) last issued its quarterly earnings data on Thursday, August 13th. The biopharmaceutical company reported $0.02 earnings per share for the quarter, topping analysts’ consensus estimates of ($0.27) by $0.29. The business had revenue of $28.53 million for the quarter, compared to analysts’ expectations of $12.69 million. As a group, research analysts expect that Omeros Corporation will post -0.37 earnings per share for the current year.

Wall Street Analyst Weigh In

A number of brokerages have weighed in on OMER. HC Wainwright reissued a “buy” rating on shares of Omeros in a research note on Monday, July 27th. Wall Street Zen upgraded Omeros from a “hold” rating to a “buy” rating in a research note on Saturday, August 15th. Zacks Research downgraded Omeros from a “strong-buy” rating to a “hold” rating in a research report on Monday, July 13th. Finally, Weiss Ratings raised Omeros from a “sell (d+)” rating to a “hold (c-)” rating in a research note on Wednesday, August 5th. One investment analyst has rated the stock with a Strong Buy rating, two have issued a Buy rating and three have issued a Hold rating to the company. According to MarketBeat, the company has an average rating of “Moderate Buy” and an average price target of $38.00.

Institutional Investors Weigh In On Omeros

A number of institutional investors have recently added to or reduced their stakes in OMER. State of Wyoming acquired a new position in shares of Omeros in the 4th quarter valued at about $25,000. B. Riley Wealth Advisors Inc. acquired a new stake in Omeros during the 2nd quarter worth approximately $32,000. Caitong International Asset Management Co. Ltd acquired a new stake in Omeros during the 4th quarter worth approximately $33,000. Assetmark Inc. purchased a new position in Omeros in the first quarter valued at approximately $38,000. Finally, Tower Research Capital LLC TRC lifted its position in Omeros by 829.6% during the second quarter. Tower Research Capital LLC TRC now owns 13,414 shares of the biopharmaceutical company’s stock valued at $40,000 after buying an additional 11,971 shares in the last quarter. Hedge funds and other institutional investors own 48.79% of the company’s stock.

About Omeros

Omeros Corporation is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of small-molecule and protein therapeutics. The company’s research programs target inflammation, complement-mediated diseases and disorders of the central nervous system. Omeros’s portfolio encompasses both internally discovered molecules and biologics, reflecting its commitment to advancing treatments for conditions with high unmet medical need.

Omeros’s first FDA-approved product, Omidria® (phenylephrine and ketorolac intraocular solution), is indicated to maintain pupil size by preventing intraoperative miosis and reducing postoperative pain in patients undergoing cataract surgery.